Upadacitinib 56-wk efficacy/safety (mod to severe PsA) 🔹Comparable or ⬆️efficacy vs adalimumab 🔹Efficacy maintained, and 15mg vs 30mg doses similar at 56wks 🔹No new safety findings @ 56wks 🔹🚫inc risk VTE, MACE, cancer vs ada https://t.co/NlKvBrwDxB #ACR21 Abst#1345 @RheumNow

• Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic A…

Interesting question came up: why would you change a RA patient from JAKi to JAKi? The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way). That would clearly favour to better survival #ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit

• Richard Conway on Twitter: "JAK-pot registry-based study. Following JAKi f…

JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to second JAKi? Both seem equally effective in terms of drug retention. Didn't matter if switch for efficacy or adverse event. Abstr#1442 #ACR21 @RheumNow https://t.co/QEBB3flArC

#ACR21 Abs#1442: JAKpot - Cycle JAK or switch to bDMARD after JAK failure? ▶️No difference between cycle vs bDMARD group ▶️Non-signif trends: cycled JAK better for inefficacy to 1st JAK, bDMARD better for adverse effects @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/upfI6tDH1p

• https://bit.ly/3qk9MB2

First JAKi failure: What's next? Wanna find out? It's here https://t.co/o5CE1MBzUu Abstr#1442 #ACR21 @RheumNow https://t.co/f0sdPn5mcZ

• First JAKi Failure: What next? Dr. Aurelie Najm | RheumNow

⭐️ Wanna catch up with the latest news on JAKi safety trials presented at #ACR21? Our @Rheumnow interview with @ErnestChoy1 is out. Link below https://t.co/zYb4rXcw1x https://t.co/i39xXnfC3Q

• JAKi Safety: Dr. Ernest Choy with Dr. Aurelie Najm - YouTube

Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use. ⭐️>60% w/ background csDMARD use, majority of which was MTX ⭐️no difference in AE #ACR21 Abs#1352 @RheumNow https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo

• Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Ex…